メールサービス キャンペーン : 期間中に新規登録や配信希望カテゴリの変更等をされた方に、ご用意した無料レポートを提供しております。 新規登録 / 登録内容変更

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

Bionomics Limited:製品パイプライン分析

Bionomics Ltd - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 256101
出版日 ページ情報 英文 47 Pages
即納可能
価格
本日の銀行送金レート: 1USD=110.90円で換算しております。
Back to Top
Bionomics Limited:製品パイプライン分析 Bionomics Ltd - Product Pipeline Review - 2016
出版日: 2016年12月30日 ページ情報: 英文 47 Pages
概要

Bionomics Limited は、癌や、不安神経症・うつ病・アルツハイマー病といった中枢神経系疾患の治療薬を開発しているバイオ製薬会社です。また、免疫疾患の治療薬も提供しています。

当レポートでは、Bionomics Limitedにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Bionomics Limitedの基本情報

Bionomics Limitedの概要

  • 主要情報
  • 企業情報

Bionomics Limited:R&Dの概要

  • 主な治療範囲

Bionomics Limited:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • アウトライセンス製品
    • アウトライセンス製品/併用療法モダリティ

Bionomics Limited:パイプライン製品の概況

  • 治験段階にあるパイプライン製品
    • 第II相にある製品/併用療法モダリティ
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ
    • 創薬中の製品/併用療法モダリティ

Bionomics Limited:薬剤プロファイル

  • BNC-105
  • BNC-105P
  • BNC-210
  • BL-011256
  • BNC-101
  • BNC-164
  • BNC-420
  • BNC-102
  • Programs for Cancer
  • Small Molecules to Agonize GABA-A Receptor For Epilepsy
  • Small Molecules to Block Nav 1.7 Channels for Chronic And Neuropathic Pain

Bionomics Limited:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Bionomics Limited:最近のパイプライン動向

Bionomics Limited:休止中のプロジェクト

Bionomics Limited:開発が中止されたパイプライン製品

  • 開発が中止されたパイプライン製品のプロファイル
    • Drug to Inhibit RET Kinase for Lung and Thyroid Cancer

Bionomics Limited:本社と子会社の所在地

付録

図表

目次
Product Code: GMDHC08175CDB

Summary:

Global Markets Direct's, 'Bionomics Ltd - Product Pipeline Review - 2016', provides an overview of the Bionomics Ltd's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Bionomics Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the pipeline therapeutic landscape of Bionomics Ltd
  • The report provides overview of Bionomics Ltd including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Bionomics Ltd's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Bionomics Ltd's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy:

  • Evaluate Bionomics Ltd's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Bionomics Ltd
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Bionomics Ltd's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Bionomics Ltd Snapshot
    • Bionomics Ltd Overview
    • Key Facts
  • Bionomics Ltd - Research and Development Overview
    • Key Therapeutic Areas
  • Bionomics Ltd - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Bionomics Ltd - Pipeline Products Glance
    • Bionomics Ltd - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Bionomics Ltd - Early Stage Pipeline Products
      • IND/CTA Filed Products/Combination Treatment Modalities
      • Preclinical Products/Combination Treatment Modalities
  • Bionomics Ltd - Drug Profiles
    • BL-011256 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BNC-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BNC-105 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BNC-164 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BNC-210 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BNC-420 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug for Dyskinesia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug for Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs for Solid Tumors - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs to Inhibit MELK for Solid Tumors - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize GABA-A Receptor For Epilepsy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Block Nav 1.7 Channels for Chronic And Neuropathic Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Bionomics Ltd - Pipeline Analysis
    • Bionomics Ltd - Pipeline Products by Target
    • Bionomics Ltd - Pipeline Products by Route of Administration
    • Bionomics Ltd - Pipeline Products by Molecule Type
    • Bionomics Ltd - Pipeline Products by Mechanism of Action
  • Bionomics Ltd - Dormant Projects
  • Bionomics Ltd - Discontinued Pipeline Products
  • Discontinued Pipeline Product Profiles
  • Drug to Inhibit RET Kinase for Lung and Thyroid Cancer
  • Bionomics Ltd - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Bionomics Ltd, Key Facts
  • Bionomics Ltd - Pipeline by Indication, 2016
  • Bionomics Ltd - Pipeline by Stage of Development, 2016
  • Bionomics Ltd - Monotherapy Products in Pipeline, 2016
  • Bionomics Ltd - Out-Licensed Products in Pipeline, 2016
  • Bionomics Ltd - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Bionomics Ltd - Phase II, 2016
  • Bionomics Ltd - Phase I, 2016
  • Bionomics Ltd - IND/CTA Filed, 2016
  • Bionomics Ltd - Preclinical, 2016
  • Bionomics Ltd - Pipeline by Target, 2016
  • Bionomics Ltd - Pipeline by Route of Administration, 2016
  • Bionomics Ltd - Pipeline by Molecule Type, 2016
  • Bionomics Ltd - Pipeline Products by Mechanism of Action, 2016
  • Bionomics Ltd - Dormant Developmental Projects,2016
  • Bionomics Ltd - Discontinued Pipeline Products, 2016
  • Bionomics Ltd, Subsidiaries

List of Figures

  • Bionomics Ltd - Pipeline by Top 10 Indication, 2016
  • Bionomics Ltd - Pipeline by Stage of Development, 2016
  • Bionomics Ltd - Monotherapy Products in Pipeline, 2016
  • Bionomics Ltd - Pipeline by Target, 2016
  • Bionomics Ltd - Pipeline by Route of Administration, 2016
  • Bionomics Ltd - Pipeline by Molecule Type, 2016
  • Bionomics Ltd - Pipeline Products by Mechanism of Action, 2016
Back to Top